Cancer medicine 2018 03 23() doi 10.1002/cam4.1408
The aim of this study was to examine long-term outcomes in patients who received salvage radiotherapy (SRT) for biochemical recurrence (BRec) of prostate cancer after radical prostatectomy (RP). One hundred and twenty patients with prostate cancer who underwent SRT for BRec after RP without evidence of clinical disease were identified in our institution from 2002 to 2014. Prescription doses to prostate beds were 64.8 Gy with a fractional dose of 1.8 Gy in 96.7% of the patients. In three-dimensional conformal radiation therapy (3D-CRT), the seminal vesicle bed (SVB) was not included in the radiation fields. The prognostic factors for BRec-free survival (BRFS) and incidence of acute and late toxicities were investigated. Median follow-up duration after SRT was 64.9 months. The 5-year rates of BRFS, overall survival (OS), cause-specific survival (CSS), and clinical recurrence-free survival (CRFS) were 39.2%, 98.3%, 97.0%, and 91.9%, respectively. Only two patients experienced late grade 3 toxicity of hematuria. Multivariate analysis revealed that BRFS was significantly favorable in patients with prostate-specific antigen (PSA) values <0.5 ng/mL at the initiation of SRT and pathological Gleason score not including Gleason grade 5. In patients treated with 3D-CRT, a positive surgical margin at the base of the prostate influenced BRFS unfavorably in comparison with positive surgical margins at other sites. SRT for patients with BRec after RP was performed very safely in our institution. However, to improve BRFS, adequate inclusion of the SVB appears mandatory, especially in cases of positive surgical margins at the base of the prostate.